SCHEMBL25166306

SCHEMBL25166306

CC(C)(C)OC(=O)Nc1cc(OCCCCl)c2c(c1)OCCO2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MTNR1A P48039 4/20 0.40
RAB9A P51151 7/20 0.39
PLK1 P53350 1/20 0.36
MAPT P10636 6/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPK1 P28482 1/20 0.35
KDM4E B2RXH2 2/20 0.35
HTT P42858 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35
ALOX15 P16050 1/20 0.34
NPC1 O15118 6/20 0.34
LMNA P02545 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TP53 P04637 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31108023 1.00 MEN1 (0.46) MEN1KMT2AHPGDNPSR1MTNR1A
SCHEMBL30330289 0.91 NPC1 (0.39) MEN1KMT2AHPGDNPSR1RAB9A
SCHEMBL30330061 0.86 ACHE (0.46) MEN1KMT2AHPGDNPSR1ALDH1A1
SCHEMBL31108052 0.86 ACHE (0.46) MEN1KMT2AHPGDNPSR1ALDH1A1
SCHEMBL30330164 0.84 HTR1D (0.35) MEN1KMT2AHPGDNPSR1ALDH1A1
SCHEMBL25166343 0.82 NPSR1 (0.47) MEN1KMT2AHPGDNPSR1MTNR1A
SCHEMBL25166337 0.78 HPGD (0.50) MEN1KMT2AHPGDNPSR1RAB9A
SCHEMBL31107875 0.78 HPGD (0.50) MEN1KMT2AHPGDNPSR1RAB9A
SCHEMBL25166285 0.77 ACHE (0.46) ALDH1A1KDM4EHTTTSHR
SCHEMBL25166436 0.77 SCD (0.40) KMT2ARORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 US disclosed
EP-4416143-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-08-21 EP disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 MEN1 1847/4885KMT2A 33/4885HPGD 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.